You are here

Article Text

Article menu
Download PDFPDF
Research letter
A big beautiful wall against infection
  1. Gisli Jenkins
  1. Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  1. Correspondence to Professor Gisli Jenkins, Centre for Respiratory Research, University of Nottingham, Nottingham NG51PB, UK; gisli.jenkins{at}nottingham.ac.uk

https://doi.org/10.1136/thoraxjnl-2017-211220

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Humankind’s greatest enemy has always been, and likely will always be, infection. The role of infection in idiopathic pulmonary fibrosis (IPF) is a poorly understood but the emergence of molecular techniques has renewed the focus on this area. Earlier studies of histological sections identified herpes virus DNA and haemophilus species in lung tissue.1 More recently, studies have used high sensitivity and high throughput techniques to assess bacterial species in bronchoavleoar lavage (BAL). A large number of studies have now identified divergent bacterial species in the BAL and have associated them with mechanistic processes that give biological plausibility to the role of luminal infections promoting the development of IPF.2–4

    It is therefore somewhat surprising that in the study by …

    View Full Text

    Footnotes

    • Competing interests GJ reports grants from GSK, UK, MRC, Biogen, MedImmune and Galecto; personal fees from Boehringer Ingleheim, GSK, Intermune, MedImmune, PharmAkea, Roche, Pulmatrix, Pliant Therapeutics and NuMedii. GJ is a Trustee for the charities Action for Pulmonary Fibrosis and the British Thoracic Society.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles